# Osteosarcoma Aspirin is more interesting in **osteosarcoma** than most readers expect. This is still a **preclinical** page. There is no adjuvant Phase 3 aspirin trial in osteosarcoma. But the field has two things that matter. First, it has a landmark **2015 Clinical Cancer Research** paper showing direct anti-tumour and anti-metastatic activity. Second, it now has a newer mechanistic layer through **PDE4D**, which may help explain why aspirin is relevant in this disease beyond its broader anti-inflammatory profile. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) The clinical importance is also unusually clear. The two hardest osteosarcoma problems are **lung metastasis** and **cisplatin resistance**. Those are exactly the areas where aspirin has shown the most direct mechanistic relevance. [Read the 2026 paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) ### Overview Osteosarcoma is the most common primary malignant bone tumour. It affects mainly **children**, **adolescents**, and **young adults**. Survival remains much worse once metastatic disease is present, especially when the lungs are involved. Aspirin matters here mainly through **NF-κB suppression**. That pathway helps drive osteosarcoma cell survival, migration, invasion, and treatment resistance. Aspirin has repeatedly been shown to suppress this pathway in osteosarcoma models. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) The newer **PDE4D** finding adds a second angle. It suggests aspirin may also dismantle a more specific osteosarcoma growth program linked to poorer outcomes. [Read the 2026 paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) ### Key findings #### The landmark 2015 AACR study This remains the core osteosarcoma aspirin paper. In this work, aspirin showed direct anti-tumour effects across osteosarcoma models and also affected the parts of the disease that matter most clinically. [Read the paper](https://aacrjournals.org/clincancerres/article/21/23/5349/262254/Aspirin-Suppresses-the-Growth-and-Metastasis-of) Key findings included: * aspirin reduced osteosarcoma cell viability in a **dose-dependent** and **time-dependent** way * aspirin **sensitised osteosarcoma cells to cisplatin** in both cell-line and animal models * aspirin reduced **migration** and **invasion** in vitro * aspirin **markedly reduced lung metastases** in osteosarcoma xenograft models * the mechanism was linked to **NF-κB pathway suppression** The lung-metastasis result is the most important part of the paper. In osteosarcoma, lung spread is the dominant metastatic pattern and a major reason survival falls so sharply in advanced disease. A preclinical finding that directly reduces pulmonary metastasis is therefore more meaningful here than a generic anti-proliferative result. #### The 2026 PDE4D finding The 2026 paper adds something genuinely new. It identified **PDE4D** as a highly expressed oncogenic driver in osteosarcoma and linked higher expression to worse patient outcomes. Aspirin was shown to suppress **PDE4D** through the **NF-κB / p65 → PDE4D promoter** axis. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) That matters for three reasons: * it gives osteosarcoma a more specific aspirin-sensitive target * it helps explain anti-proliferative effects that are not fully captured by broad NF-κB language alone * it raises the possibility that **PDE4D-high tumours** could become a future biomarker-defined subgroup This is still early. But it is the kind of finding that can shift a page from “interesting old mechanism” to “active evolving research area.” #### Earlier cell-line evidence A 2011 MG-63 cell-line study also reported direct anti-proliferative effects of aspirin in osteosarcoma cells. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/22654634/) That older work matters less than the 2015 and 2026 studies, but it helps show continuity. The aspirin signal in osteosarcoma was not a one-off observation. ### Mechanistic relevance #### NF-κB suppression This is the central osteosarcoma mechanism. **NF-κB** is persistently active in many osteosarcoma models and supports: * tumour-cell survival * resistance to apoptosis * migration and invasion * angiogenesis-related signalling * chemotherapy resistance, including cisplatin resistance Aspirin suppresses this pathway and lowers downstream invasion and metastasis signals. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) #### Cisplatin sensitisation This is one of the most clinically relevant osteosarcoma findings. Cisplatin remains one of the core drugs in osteosarcoma treatment. Resistance to it is a major problem in relapsed or refractory disease. The 2015 study showed that aspirin and cisplatin worked **synergistically**, not just additively, in osteosarcoma models. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) That does not prove clinical benefit yet. But it does make osteosarcoma one of the clearer aspirin pages for chemotherapy-sensitisation logic. #### Lung metastasis and platelet biology The 2015 osteosarcoma paper showed a direct reduction in **lung metastases**. A second mechanistic layer comes from broader platelet biology. Circulating tumour cells can use platelet-derived **TXA2** and platelet cloaking to evade immune killing during metastatic spread. That systemic mechanism was clarified in the 2025 **Nature** work on the **TXA2 → ARHGEF1 → CD8-positive T-cell suppression** axis. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) There is no osteosarcoma-specific randomised trial proving this pathway explains the metastasis result. But the biology is coherent. In a disease where lung dissemination is the main metastatic threat, aspirin's platelet and **TXA2** effects are highly relevant. For the broader mechanism, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). #### PDE4D and cAMP signalling **PDE4D** breaks down intracellular **cAMP**. Because cAMP can restrain proliferation in some tumour contexts, higher PDE4D activity can help create a more growth-permissive environment. By downregulating PDE4D, aspirin may shift intracellular signalling in an anti-proliferative direction in osteosarcoma cells. [Read the 2026 paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) That makes PDE4D one of the most interesting new osteosarcoma biomarkers to watch. ### VTE prophylaxis context Aspirin is also relevant in osteosarcoma for a different reason. Orthopaedic-oncology patients have meaningful **venous thromboembolism** risk, especially around large limb-sparing procedures, reconstructions, and reduced mobility. A current trial is comparing **low molecular weight heparin** with **aspirin** for postoperative VTE prophylaxis in orthopaedic-oncology patients. [Read the trial record](https://clinicaltrials.gov/study/NCT03244020) This is not an anti-tumour aspirin trial. But it still matters because it shows aspirin is already entering formal clinical infrastructure in the surgical bone-oncology setting. ### Clinical positioning | Setting | Evidence | Position | | ------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------------------------- | | **Direct anti-tumour activity in osteosarcoma models** | Repeated cell-line and animal-model signal. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) | Strong preclinical foundation | | **Lung-metastasis suppression** | In vivo xenograft evidence with clear reduction in pulmonary spread. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) | Most clinically important finding | | **Cisplatin sensitisation** | Synergistic preclinical effect in vitro and in vivo. [Read the 2015 paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) | Directly relevant to resistant disease | | **PDE4D-high tumours** | New 2026 biomarker and mechanistic target. [Read the 2026 paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) | Important emerging direction | | **TXA2 and platelet-linked metastasis biology** | Strong systemic rationale, but not osteosarcoma-trial validated. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) | Biologically coherent | | **Postoperative VTE prophylaxis** | Active clinical-trial use in orthopaedic oncology. [Read the trial record](https://clinicaltrials.gov/study/NCT03244020) | Real-world clinical relevance, but different question | | **Human adjuvant anti-tumour trial data** | None | Investigational only | ### Honest evidence assessment This page is still **entirely preclinical** on the anti-tumour side. That limit matters. There is no human trial showing that aspirin improves metastasis-free survival, overall survival, or chemotherapy response in osteosarcoma patients. Even so, the page is stronger than many purely mechanistic pages because the preclinical findings are tightly aligned with the disease's main clinical failure points: * **lung metastasis** * **cisplatin resistance** The newer **PDE4D** work also adds a plausible future biomarker story rather than just repeating generic anti-inflammatory biology. ### Practical interpretation This is a page worth following, especially for families dealing with relapsed, metastatic, or high-risk osteosarcoma. The most useful questions are: 1. Is the key issue **lung metastasis**, **cisplatin resistance**, or both? 2. Has anyone discussed the tumour's **NF-κB** or possibly future **PDE4D** relevance? 3. Is aspirin being discussed in a **surgical VTE-prevention** context, which is a different question from direct anti-tumour use? 4. In younger patients, has the team weighed age-specific aspirin safety, bleeding risk, and perioperative timing carefully? That last point matters. Because osteosarcoma often affects children and adolescents, aspirin should not be treated as a casual add-on. Any discussion belongs with the **paediatric oncology** or **orthopaedic oncology** team. ### References * Tian et al., *Clinical Cancer Research* 2015 — aspirin suppresses osteosarcoma growth and metastasis through **NF-κB**-linked mechanisms. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/26202947/) * AACR journal version of the 2015 study — includes the lung-metastasis findings. [Read the journal article](https://aacrjournals.org/clincancerres/article/21/23/5349/262254/Aspirin-Suppresses-the-Growth-and-Metastasis-of) * 2026 study — aspirin downregulates **PDE4D** via the **NF-κB / p65** axis in osteosarcoma. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/41540519/) * 2011 MG-63 cell-line study — early anti-proliferative evidence for aspirin in osteosarcoma. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/22654634/) * Yang et al., *Nature* 2025 — platelet **TXA2**, immune escape, and metastatic spread. [Read the Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) * Orthopaedic-oncology VTE trial — aspirin versus low molecular weight heparin after surgery. [Read the trial record](https://clinicaltrials.gov/study/NCT03244020)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/osteosarcoma.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.